Commitments and Contingent Liabilities (Details) ₪ in Thousands, $ in Thousands |
1 Months Ended | 3 Months Ended | 12 Months Ended | |||||||
|---|---|---|---|---|---|---|---|---|---|---|
Apr. 30, 2019 |
Dec. 31, 2017
USD ($)
|
May 31, 2017
USD ($)
|
Jun. 30, 2015
USD ($)
|
Mar. 31, 2020
USD ($)
|
Mar. 31, 2020
ILS (₪)
|
Dec. 31, 2019
USD ($)
|
Dec. 31, 2019
ILS (₪)
|
Dec. 31, 2017
USD ($)
|
Dec. 31, 2019
ILS (₪)
|
|
| Commitments and Contingent Liabilities (Textual) | ||||||||||
| Approved budget | $ 726 | |||||||||
| Percentage of approved budget | 85.00% | 85.00% | 30.00% | 30.00% | ||||||
| Contingent obligation | $ 2,200 | |||||||||
| New application of total budget amount | $ 3,100 | |||||||||
| Other commitments, description | The program is for the period beginning from January 2020 through December 2020. | The program is for the period beginning from January 2020 through December 2020. | The program is for the period beginning from July 2019 through December 2019. | The program is for the period beginning from July 2019 through December 2019. | ||||||
| Additional budget | $ 11,900 | |||||||||
| Granted commitment loans | One loan was granted in the amount of $19 thousand. and the aggregate amount of the remaining potential commitment is $89 thousand. All other shareholders waived their right to the loans. The numbers of common stock in respect of which the $19 loan was granted was 5,700. | One loan was granted in the amount of $19 thousand. and the aggregate amount of the remaining potential commitment is $89 thousand. All other shareholders waived their right to the loans. The numbers of common stock in respect of which the $19 loan was granted was 5,700. | ||||||||
| Amount of liabilities recorded to agreement | $ 234 | 217 | ||||||||
| License and Maintenance [Member] | ||||||||||
| Commitments and Contingent Liabilities (Textual) | ||||||||||
| Other commitments, description | BiomX Israel is also required to make payments to MIT upon the satisfaction of development and commercialization milestones totaling up to $2.4 million in aggregate as well as royalty payments on future revenues. As the Company has not yet generated revenues, the interim consolidated statements of operations for the three months ended March 31, 2020 and 2019 include a liability with respect to this agreement in the amount of $123 and $108 thousand, respectively. | BiomX Israel is also required to make payments to MIT upon the satisfaction of development and commercialization milestones totaling up to $2.4 million in aggregate as well as royalty payments on future revenues. As the Company has not yet generated revenues, the interim consolidated statements of operations for the three months ended March 31, 2020 and 2019 include a liability with respect to this agreement in the amount of $123 and $108 thousand, respectively. | ||||||||
| Annual license fees | $ 25 | |||||||||
| Maximum payments of license maintenance fees | $ 250 | |||||||||
| License Agreement [Member] | ||||||||||
| Commitments and Contingent Liabilities (Textual) | ||||||||||
| Approved budget | $ 1,800 | |||||||||
| Annual license fees | $ 10 | |||||||||
| NIS [Member] | ||||||||||
| Commitments and Contingent Liabilities (Textual) | ||||||||||
| Approved budget | ₪ | ₪ 2,700 | |||||||||
| New application of total budget amount | ₪ | ₪ 10,800 | |||||||||
| Additional budget | ₪ | ₪ 41,100 | |||||||||
| 2017 License Agreement [Member] | ||||||||||
| Commitments and Contingent Liabilities (Textual) | ||||||||||
| Consideration percentage | 1.00% | |||||||||
| Annual license fees | $ 10,000 | $ 10,000 | ||||||||
| Additional Lease Agreements [Member] | ||||||||||
| Commitments and Contingent Liabilities (Textual) | ||||||||||
| Additional budget | $ 4,400 | |||||||||
| Commitments and Contingent Liabilities, description | (i) to pay a license issue fee of $20,000 and annual license fees ranging from $15,000 to $25,000 and (ii) make additional payments based upon the achievement of clinical and regulatory milestones up to an aggregate of $3.2 million (“milestone payments”) and (iii) make tiered royalty payments, in the low single digits based on future revenue. | The Company will pay annual license fees of between $15,000 to $25,000 subject to the terms and conditions specified in the agreement. Additionally, the Company is obligated to make additional payments based upon the achievement of clinical and regulatory milestones up to an aggregate of $3.2 million and royalty payments based on future revenue. | ||||||||
| Additional Lease Agreements [Member] | NIS [Member] | ||||||||||
| Commitments and Contingent Liabilities (Textual) | ||||||||||
| Additional budget | ₪ | ₪ 15,600 | |||||||||
| 2015 License Agreement [Member] | ||||||||||
| Commitments and Contingent Liabilities (Textual) | ||||||||||
| Consideration percentage | 1.00% | |||||||||
| Maximum [Member] | ||||||||||
| Commitments and Contingent Liabilities (Textual) | ||||||||||
| Royalties rate | 3.00% | 3.00% | ||||||||
| Annual license fees | $ 15,000 | |||||||||
| Minimum [Member] | ||||||||||
| Commitments and Contingent Liabilities (Textual) | ||||||||||
| Royalties rate | 3.50% | 3.50% | ||||||||
| Annual license fees | $ 25,000 | |||||||||